New approach methodologies reshaping drug safety testing
Posted by devin280 in Safety & Side Effects - 52 points, 4 comments.
Came across this piece on Drug Discovery News about how virtual control groups, organoids and other new methods are changing chemical safety assessment. Seems like a big shift away from traditional animal testing toward more human-relevant systems. As someone who runs bloodwork and HRV tracking with peptides, i'm curious whether these newer methods could catch subtle stuff we currently miss, things like receptor binding quirks or long-term organ effects that standard screens might overlook. The article mentions brain organoids in particular, which feels relevant given how much compounds can affect neurochemistry.
Honestly i'm skeptical the industry will drop animal models entirely anytime soon, too much regulatory inertia and cost structures built around the old way. But if these new approaches can flag risks earlier, that's a win for everyone running compounds. Leaves me wondering whether we'll see safety protocols shift to require these newer validation steps before compounds hit the research space, or if it'll just be additive on top of existing requirements. Would love to hear what others think about whether this changes anything for personal compounding protocols.
Comments
- steph544: Anecdotally i think the organoid stuff is huge for neuro stuff. I have been messing with some ghrp stuff and felt some weird mood swings that i couldnt quite pin down. If they could have run that through a brain organoid model maybe they would have caught how it hits those receptors differently for some people... It feels like it'll just be additive. The fda is slow as hell so they aren't gonna ditch the old ways easily. But having more human-relevant data would definitely be better for us tryi
- devin280: I think you hit the nail on the head about it being additive. The fda isnt moving fast for anyone. Those mood swings with your ghrp research sound annoying. For me, it's hard to tell if my own mood shifts are just lifestyle or the peptides, but better human models would definitely help clear that up. Do you think the swings were tied to specific doses?
- theo149: Fair play, I reckon you are spot on about the FDA being slow. They love their traditional models even if they are a bit rubbish for predicting human neuro responses. For me, those mood swings with GHRPs were a bit gas too, but it could just be my sleep or something else entirely. More data on receptor binding would be class.
- devin280: Honestly i had similar mood shifts when i first started with ghrps. My hrv dipped quite a bit and i felt weirdly agitated, though it could just be the heat here in singapore. I wonder if better receptor binding data would show if those swings are tied to specific pulses or just general systemic stress. We are just guessing with the current data, which is why these organoids would be shiok if they actually work.
Community discussion - research and educational context only. Not medical advice.